Furoscix® (furosemide) – New drug approval

- On October 10, 2022, scPharmaceuticals announced the FDA approval of Furoscix (furosemide), for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
    - Furoscix is not indicated for use in emergency situations or in patients with acute pulmonary edema. The On-Body Infusor will deliver only an 80-mg dose of Furoscix.
- Furoscix is the first FDA-approved subcutaneous loop diuretic that delivers IV equivalent diuresis at home via the Furoscix On-Body Infusor.
- Furoscix is contraindicated in patients with:
    - Anuria
    - A history of hypersensitivity to furosemide or medical adhesives
    - Hepatic cirrhosis or ascites
- Warnings and precautions for Furoscix include fluid, electrolyte, and metabolic abnormalities; worsening renal function; ototoxicity; and acute urinary retention.
- The most common adverse reactions with Furoscix use were administration site and skin reactions (erythema, bruising, edema, and infusion site pain).
- The single-use, On-Body Infusor with prefilled cartridge is pre-programed to deliver 30 mg of Furoscix over the first hour followed by 12.5 mg per hour for the subsequent 4 hours.
    - Furoscix is not for chronic use and should be replaced with oral diuretics as soon as practical.
- scPharmaceuticals plans to launch Furoscix in the first quarter 2023. Furoscix will be available as an 80 mg/10 mL solution in a single-dose prefilled cartridge for use only with co-packaged single-use, On-Body Infusor.